AKRO
Price
$53.81
Change
+$0.15 (+0.28%)
Updated
Oct 14 closing price
Capitalization
4.31B
28 days until earnings call
Intraday Buy/Sell Signals
ENTA
Price
$11.15
Change
+$0.19 (+1.73%)
Updated
Oct 15, 11:15 AM (EDT)
Capitalization
316.23M
33 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

AKRO vs ENTA

Header iconAKRO vs ENTA Comparison
Open Charts AKRO vs ENTABanner chart's image
Akero Therapeutics
Price$53.81
Change+$0.15 (+0.28%)
Volume$2.23M
Capitalization4.31B
Enanta Pharmaceuticals
Price$11.15
Change+$0.19 (+1.73%)
Volume$177
Capitalization316.23M
AKRO vs ENTA Comparison Chart in %
View a ticker or compare two or three
VS
AKRO vs. ENTA commentary
Oct 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKRO is a Hold and ENTA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 15, 2025
Stock price -- (AKRO: $53.81 vs. ENTA: $10.96)
Brand notoriety: AKRO and ENTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKRO: 102% vs. ENTA: 52%
Market capitalization -- AKRO: $4.31B vs. ENTA: $316.23M
AKRO [@Biotechnology] is valued at $4.31B. ENTA’s [@Biotechnology] market capitalization is $316.23M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKRO’s FA Score shows that 1 FA rating(s) are green whileENTA’s FA Score has 1 green FA rating(s).

  • AKRO’s FA Score: 1 green, 4 red.
  • ENTA’s FA Score: 1 green, 4 red.
According to our system of comparison, both AKRO and ENTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKRO’s TA Score shows that 3 TA indicator(s) are bullish while ENTA’s TA Score has 6 bullish TA indicator(s).

  • AKRO’s TA Score: 3 bullish, 6 bearish.
  • ENTA’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, ENTA is a better buy in the short-term than AKRO.

Price Growth

AKRO (@Biotechnology) experienced а +16.98% price change this week, while ENTA (@Biotechnology) price change was -1.08% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.76%. For the same industry, the average monthly price growth was +13.99%, and the average quarterly price growth was +268.92%.

Reported Earning Dates

AKRO is expected to report earnings on Nov 12, 2025.

ENTA is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+0.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AKRO($4.31B) has a higher market cap than ENTA($316M). AKRO (93.422) and ENTA (90.609) have similar YTD gains . ENTA has higher annual earnings (EBITDA): -82.41M vs. AKRO (-279.17M). AKRO has more cash in the bank: 742M vs. ENTA (204M). AKRO has less debt than ENTA: AKRO (37.2M) vs ENTA (58M). ENTA has higher revenues than AKRO: ENTA (64.8M) vs AKRO (0).
AKROENTAAKRO / ENTA
Capitalization4.31B316M1,365%
EBITDA-279.17M-82.41M339%
Gain YTD93.42290.609103%
P/E RatioN/AN/A-
Revenue064.8M-
Total Cash742M204M364%
Total Debt37.2M58M64%
FUNDAMENTALS RATINGS
AKRO vs ENTA: Fundamental Ratings
AKRO
ENTA
OUTLOOK RATING
1..100
5484
VALUATION
overvalued / fair valued / undervalued
1..100
29
Undervalued
99
Overvalued
PROFIT vs RISK RATING
1..100
78100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
4637
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKRO's Valuation (29) in the null industry is significantly better than the same rating for ENTA (99) in the Biotechnology industry. This means that AKRO’s stock grew significantly faster than ENTA’s over the last 12 months.

AKRO's Profit vs Risk Rating (78) in the null industry is in the same range as ENTA (100) in the Biotechnology industry. This means that AKRO’s stock grew similarly to ENTA’s over the last 12 months.

AKRO's SMR Rating (97) in the null industry is in the same range as ENTA (98) in the Biotechnology industry. This means that AKRO’s stock grew similarly to ENTA’s over the last 12 months.

ENTA's Price Growth Rating (37) in the Biotechnology industry is in the same range as AKRO (46) in the null industry. This means that ENTA’s stock grew similarly to AKRO’s over the last 12 months.

ENTA's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for AKRO (100) in the null industry. This means that ENTA’s stock grew significantly faster than AKRO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKROENTA
RSI
ODDS (%)
Bullish Trend 8 days ago
81%
Bearish Trend 8 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 8 days ago
85%
Bearish Trend 8 days ago
72%
Momentum
ODDS (%)
Bearish Trend 8 days ago
82%
Bullish Trend 8 days ago
70%
MACD
ODDS (%)
Bullish Trend 8 days ago
85%
Bullish Trend 8 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 8 days ago
84%
Bullish Trend 8 days ago
76%
TrendMonth
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 8 days ago
78%
Advances
ODDS (%)
Bullish Trend 23 days ago
82%
Bullish Trend 17 days ago
71%
Declines
ODDS (%)
Bearish Trend 9 days ago
84%
Bearish Trend 14 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 8 days ago
79%
Bearish Trend 8 days ago
83%
Aroon
ODDS (%)
Bearish Trend 8 days ago
80%
Bullish Trend 8 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
AKRO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ENTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RPMNX17.260.22
+1.29%
Reinhart Mid Cap PMV Institutional
HSPCX17.030.09
+0.53%
Emerald Growth C
JIGCX54.310.26
+0.48%
Janus Henderson Overseas C
WFSTX12.52-0.08
-0.63%
Allspring Innovation Fund - Class A
TRZBX219.76-2.08
-0.94%
T. Rowe Price Blue Chip Growth Z

AKRO and

Correlation & Price change

A.I.dvisor indicates that over the last year, AKRO has been loosely correlated with ETNB. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if AKRO jumps, then ETNB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKRO
1D Price
Change %
AKRO100%
+0.28%
ETNB - AKRO
53%
Loosely correlated
-0.07%
SLS - AKRO
42%
Loosely correlated
+2.50%
VTYX - AKRO
38%
Loosely correlated
-1.62%
MDGL - AKRO
37%
Loosely correlated
+2.19%
IDYA - AKRO
35%
Loosely correlated
+1.12%
More

ENTA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ENTA has been loosely correlated with MRUS. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ENTA jumps, then MRUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ENTA
1D Price
Change %
ENTA100%
-4.61%
MRUS - ENTA
50%
Loosely correlated
-0.02%
ORKA - ENTA
37%
Loosely correlated
+7.74%
ANAB - ENTA
35%
Loosely correlated
-1.88%
AKRO - ENTA
34%
Loosely correlated
+0.28%
VRDN - ENTA
34%
Loosely correlated
-2.76%
More